Nagesh K. Mahanthappa Scholar Rock

Nagesh K. Mahanthappa, PhD, MBA
CEO & President
Dr. Mahanthappa is a biotechnology entrepreneur with 20 years of industry experience in roles spanning discovery research through early clinical development, as well as operations and strategy. Prior to Scholar Rock, Dr. Mahanthappa was a founding employee and VP, Corporate Development at Avila Therapeutics, Inc. (acquired by Celgene Corporation in 2012). Avila discovered and developed novel covalent drugs for the treatment of cancer, autoimmune, and viral diseases. He was previously a founding employee of Alnylam Pharmaceuticals, the first biotech established to discover RNA interference therapeutics and rose to VP, Scientific & Strategic Development. Earlier professional roles include business development at Vertex Pharmaceuticals, and discovery research at Ontogeny (now Curis, Inc.) and Cambridge NeuroScience. He was also a founder of TwistDx, a DNA diagnostics company acquired by Inverness Medical Innovations (now Alere, Inc.) in 2010. Dr. Mahanthappa received his Ph.D. in Neurobiology from the California Institute of Technology, and post-doctoral training at the E.K. Shriver Center for Mental Retardation (then affiliated with Massachusetts General Hospital) and Harvard Medical School. He received his MBA from the F.W. Olin Graduate School of Management at Babson College.
Katherine J. Turner Scholar Rock

Katherine J. Turner, PhD
Senior Vice President, Research
Dr. Turner is an accomplished biotechnology executive and entrepreneur. She has served as Vice President at such pioneering companies as Genetics Institute (Protein Discovery), Wyeth (Immunology), and Biogen Idec (Validation Biology). In addition, Dr. Turner has played key scientific leadership roles in start-up companies including Attogen, Inc. Her extensive research and managerial experience encompasses more than 30 years of involvement with all aspects of biologic medicines from discovery through early development. Her areas of therapeutic area expertise include immunology, oncology, hematopoiesis and neurobiology. Dr. Turner has been responsible for the advancement of several therapeutic monoclonal antibodies, and included among several approved drugs and clinical candidates, she has played important roles in the development of Neumega®, GM-CSF, IL-13 antagonist, and PSGL-Ig. Dr. Turner received her PhD in Biochemistry from Virginia Tech, and pursued post-doctoral training at the Cortauld Institute for Biochemistry (London University) and Brandeis University.